前沿生物(688221) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥24,648,130, representing a year-on-year increase of 106.93%[5] - The net profit attributable to shareholders was a loss of ¥55,706,177.98, with a basic and diluted earnings per share of -¥0.15[5] - The company achieved operating revenue of RMB 24.65 million in Q1 2024, representing a year-on-year growth of 107%[16] - The net loss for Q1 2024 was ¥55,706,177.98, an improvement compared to a net loss of ¥75,708,310.01 in Q1 2023, reflecting a reduction in losses of approximately 26.5%[25] - The basic and diluted earnings per share was -¥0.15 for Q1 2024, an improvement from -¥0.20 in Q1 2023[25] Research and Development - Research and development expenses totaled ¥34,071,674.17, accounting for 138.23% of operating revenue, reflecting a decrease of 23.17% compared to the previous year[6] - Research and development expenses for Q1 2024 were ¥34,071,674.17, down from ¥44,347,571.68 in Q1 2023, indicating a decrease of about 23.2%[24] - The company continues to conduct post-marketing studies for Aikening® to accumulate real-world evidence for clinical application[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,083,546,736.83, down 2.64% from the end of the previous year[6] - The total assets as of Q1 2024 amounted to ¥2,083,546,736.83, slightly down from ¥2,140,126,496.24 in the previous quarter[23] - The total liabilities for Q1 2024 were ¥796,570,613.64, showing a marginal decrease from ¥797,444,408.79 in the previous quarter[23] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥43,749,418.44[5] - The cash inflow from operating activities was $46,789,224.65 in Q1 2024, compared to $35,153,191.77 in Q1 2023, representing an increase of approximately 33.5%[27] - The net cash flow from operating activities was -$43,749,418.44 in Q1 2024, an improvement from -$68,647,762.96 in Q1 2023[27] - The cash inflow from investment activities totaled $864,809,208.54 in Q1 2024, slightly down from $872,417,901.89 in Q1 2023[28] - The net cash flow from investment activities was -$307,550,372.78 in Q1 2024, a significant decline from $91,920,898.01 in Q1 2023[28] - The cash inflow from financing activities was $98,906,319.09 in Q1 2024, compared to $103,372,882.73 in Q1 2023, showing a decrease of about 4.5%[28] - The net cash flow from financing activities was $6,590,599.75 in Q1 2024, down from $18,028,002.24 in Q1 2023[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,086[12] - The top shareholder, Jianmu Pharmaceutical Co., Ltd., held 70,638,750 shares, representing 18.86% of the total shares[12] Product Performance - Core product Aikening® generated sales revenue of RMB 19.27 million, with a year-on-year increase of 75%[16] - The company experienced a 33.00% increase in operating costs, driven by the growth in sales of its product Aikening®[10] - Aikening® ART regimen demonstrated better safety and viral suppression compared to traditional ART regimens, suggesting clinical promotion[19] - The company collaborated with the China STD/AIDS Prevention Association to enhance academic promotion and recognition of Aikening®[16] - The company reported other business income of RMB 5.37 million, including RMB 4.30 million from the distribution of Veklury® in China[16] Current Assets - As of March 31, 2024, the company's total current assets amounted to RMB 1,045.70 million, a decrease from RMB 1,102.79 million as of December 31, 2023[21] - The company's cash and cash equivalents were RMB 181.95 million, down from RMB 526.66 million at the end of 2023[21] - The company reported accounts receivable of RMB 47.50 million, a decrease from RMB 63.01 million in the previous period[21]